Ando Biomedicine Co., Ltd. released its 2023 annual report detailing the company's operating performance, financial condition and governance. The report showed that the company's 2023 net loss was RMB 5.81183 billion, and the basic and diluted loss per share was RMB 0.94. The company's revenue from customer contracts is RMB6.7305 billion, mainly from pharmaceutical sales. Other income and income includes government subsidies and interest income, totaling RMB 1,1586 billion. R&D expenditure of RMB 4.05669 billion reflects the company's continued investment in innovation. Ando Bio's financial asset and debt management ensures ample liquidity to support business operations. The company's capital management objective is to maintain a stable capital ratio and maximize shareholder value without changing objectives, policies or processes during the...Show More

Ando Biomedicine Co., Ltd. released its 2023 annual report detailing the company's operating performance, financial condition and governance. The report showed that the company's 2023 net loss was RMB 5.81183 billion, and the basic and diluted loss per share was RMB 0.94. The company's revenue from customer contracts is RMB6.7305 billion, mainly from pharmaceutical sales. Other income and income includes government subsidies and interest income, totaling RMB 1,1586 billion. R&D expenditure of RMB 4.05669 billion reflects the company's continued investment in innovation. Ando Bio's financial asset and debt management ensures ample liquidity to support business operations. The company's capital management objective is to maintain a stable capital ratio and maximize shareholder value without changing objectives, policies or processes during the reporting period. As of December 31, 2023, the Company's accounts receivable was RMB9684 million and accounts payable was RMB3857 million. Cash and bank balances were RMB11.87 billion, with no significant concentration of credit risk. Ando Biotech's total commitment for the lease of facilities and machinery is RMB 1.3537 billion. The company has not declared any dividend for 2023.